SCHEMBL1939747

SCHEMBL1939747

Cc1cccc(CNC(=O)Nc2cccc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)c2)c1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.69
NTRK1 P04629 6/20 0.52
KCNH2 Q12809 3/20 0.52
NTRK2 Q16620 3/20 0.52
NTRK3 Q16288 2/20 0.52
EGFR P00533 5/20 0.51
ERBB2 P04626 5/20 0.51
ERBB3 P21860 5/20 0.51
ERBB4 Q15303 5/20 0.51
TEK Q02763 4/20 0.51
RET P07949 2/20 0.47
KDR P35968 1/20 0.47
AURKA O14965 2/20 0.45
AURKB Q96GD4 2/20 0.45
SRC P12931 3/20 0.45
PDPK1 O15530 2/20 0.45
LCK P06239 1/20 0.45
IKBKE Q14164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1941330 0.93 PDGFRB (0.70) PDGFRBNTRK1KCNH2NTRK2NTRK3
SCHEMBL1941019 0.93 PDGFRB (0.72) PDGFRBNTRK1KCNH2NTRK2NTRK3
SCHEMBL1941370 0.91 PDGFRB (0.68) PDGFRBNTRK1KCNH2NTRK2NTRK3
SCHEMBL1941042 0.90 PDGFRB (0.80) PDGFRBNTRK1KCNH2NTRK2NTRK3
SCHEMBL1940724 0.89 EGFR (0.54) PDGFRBNTRK1NTRK2EGFRERBB2
SCHEMBL1939989 0.89 PDGFRB (0.69) PDGFRBNTRK1KCNH2NTRK2NTRK3
SCHEMBL1940395 0.87 PDGFRB (0.67) PDGFRBNTRK1KCNH2NTRK2NTRK3
SCHEMBL1942517 0.87 PDGFRB (0.69) PDGFRBNTRK1KCNH2NTRK2NTRK3
SCHEMBL1939060 0.86 EGFR (0.53) PDGFRBNTRK1KCNH2NTRK2NTRK3
SCHEMBL1940721 0.86 PDGFRB (0.77) PDGFRBNTRK1KCNH2NTRK2NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP disclosed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US disclosed
CN-1726218-A Pyrrolopyrimidine derivatives PFIZER PROD INC (US) 2006-01-25 CN disclosed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037999-A1 Pyrrolopyrimidine derivatives CCNA1, CCNT1, TP53 PDGFRB 2465/4885NTRK1 4135/4885KCNH2 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.